Scientists have made a groundbreaking discovery in understanding uterine cancer's genetic landscape. The international research team uncovered five new genomic risk factors that could dramatically improve cancer risk prediction. By studying genetic data from thousands of patients, researchers gained crucial insights into how specific genes like NAV3 influence cancer development. This research opens promising avenues for potential preventive strategies and more targeted treatments.
August 11, 2025
Study finds new genomic risk factors for uterine cancer
"The more genes we find that
are responsible, the more accurately we can calculate the probability of a
woman developing endometrial cancer" - Dr. Thilo Dörk-Bousset
An international team of researchers
has identified new risk factors in DNA that promote tumour development in the
lining of the uterus.
Key Points
1
Researchers identified 5 new genomic risk locations for endometrial cancer
2
Study analyzed genetic data from 17,000 patients and 290,000 healthy women
3
NAV3 gene plays crucial role in tumor suppression
4
Around 400,000 women diagnosed with uterine cancer annually worldwide
Cancer of the lining of the
uterus, also known as endometrial cancer, is a common gynaecological cancer.
Around 400,000 women are diagnosed with the disease every year worldwide, and
around 100,000 die from it.
Common risk factors include
obesity, diabetes, and high levels of the sex hormone oestrogen. The risk of
developing endometrial cancer also increases with age.
However, around 5 per cent of
cases are due to a genetic predisposition: gene mutations that increase the
risk of cancer as the basis for a hereditary syndrome, such as Lynch syndrome
or Cowden syndrome. Yet, a large proportion of the genetic causes are still
unclear.
The team from Hannover Medical
School (MHH) in Germany discovered five new locations in the genome that are
very likely to play a role in the development of endometrial cancer.
The findings, published in the
journal eBioMedicine, increased the number of known genomic risk factors for
endometrial cancer from 16 to 21.
"This brings us one step
closer to our goal of predicting the risk of hereditary uterine cancer as
accurately as possible," said Dr. Thilo Dörk-Bousset, head of the
gynaecological research unit at MHH
"The more genes we find that
are responsible, the more accurately we can calculate the probability of a
woman developing endometrial cancer," Dörk-Bousset added.
For the study, the team collated
genetic data from national biobanks in various countries and compared the
occurrence of genetic changes in more than 17,000 patients with endometrial
cancer with the genomes of around 290,000 healthy women.
The results were then verified in
another set of study participants.
The team examined one of the new
risk genes -- called Navigator-3 (NAV3)-- in more detail in special target
lines from uterine tissue. When NAV3 was deactivated, the uterine cells grew
faster. Excessive NAV3 activity, on the other hand, led to cell death.
"These results suggest that
NAV3 normally limits cell growth in the endometrium and thus suppresses cancer
formation as a so-called tumor suppressor gene," explains Dr. Dhanya
Ramachandran, molecular biologist at MHH.
"Accordingly, NAV3 is
greatly reduced in endometrial carcinomas."
The research may help develop
potential preventive strategies and new therapeutic approaches, said the team.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment